C6461006: AN INTERVENTIONAL PHASE 1b/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY ANTITUMOR ACTIVITY AND PHARMACOKINETICS OF PF08634404 MONOTHERAPY OR IN COMBINATION WITH ENFORTUMAB VEDOTIN IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER
Learn More About This Study
